Phase 3 Bladder Cancer Trial, Recruiting NCT07480356 Sponsor: Protara Therapeutics Condition: Bladder Cancer
Back to Bladder Cancer

Phase 3 Bladder Cancer Trial, Recruiting

NCT07480356
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older at the time of signing the consent form
  • People who have voluntarily signed a written consent form after having the study explained to them
  • People with a confirmed diagnosis (verified by a central laboratory) of high-grade non-muscle invasive bladder carcinoma in situ (CIS), which may also involve certain early-stage bladder changes (Ta or T1)
  • People who have never received BCG treatment, OR whose last BCG treatment was at least 24 months before their most recent CIS diagnosis, OR who received no more than 2 doses of BCG within the 24 months before their most recent CIS diagnosis

Who may not be able to join:

  • People with a penicillin allergy (those with an uncertain allergy history will be asked to have a blood test at a central laboratory to check)
  • People whose bladder cancer biopsy results show a variant type of cancer cells, as confirmed by a central laboratory
  • People who have cancer involvement in the prostate or upper urinary tract, as determined by the treating doctor
  • People who have had, or currently have, cancer that has spread to lymph nodes or other parts of the body at any point in their history
  • People who have had bladder cancer that has grown into the muscle layer of the bladder (T2 or higher) at any point in their history

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 16468440337

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Protara Therapeutics
Registry
ClinicalTrials.gov
Start date
29 May 2026
Est. completion
1 April 2028

Where this trial is recruiting

🇺🇦 Ukraine 🇺🇸 United States

Primary endpoints

Incidence of high-grade complete response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov